Furo [3, 2-b] indole Derivatives. V. Synthesis and Structure-Activity Studies of 4-Substituted 2- (4-Methylpiperazinylcarbonyl) -6-trifluoromethylfuro [3, 2-b] indole Derivatives with Analgesic and Antiinflammatory Activities

Based on the quantitative structure-activity relationships (QSAR) of 4, 6-disubstituted 2-morpholinocarbonylfuro [3, 2-b] indole derivatives (53 compounds) previously reported, 4-substituted 2- (4-methylpiperazinylcarbonyl) -6-trifluoromethylfuro [3, 2-b] indole derivatives (12 compounds) were synth...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Chemical & pharmaceutical bulletin 1987/01/25, Vol.35(1), pp.402-408
Hauptverfasser: KAWASHIMA, YUTAKA, OKUYAMA, SHIGERU, SATO, MASAKAZU, HATADA, YUICHI, AMANUMA, FUSAO, NAKASHIMA, YOSHIMOTO, SOTA, KAORU, MORIGUCHI, IKUO
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Based on the quantitative structure-activity relationships (QSAR) of 4, 6-disubstituted 2-morpholinocarbonylfuro [3, 2-b] indole derivatives (53 compounds) previously reported, 4-substituted 2- (4-methylpiperazinylcarbonyl) -6-trifluoromethylfuro [3, 2-b] indole derivatives (12 compounds) were synthesized. Their analgesic and antiinflammatory activities were examined by using the acetic acid writhing test in mice and the carrageenin edema test in rats, respectively. Most of these compounds showed potent analgesic and antiinflammatory activities as compared with tiaramide. The QSAR of the furo [3, 2-b] indole derivatives (65 compounds) including the newly synthesized compounds was analyzed by using the adaptive least-squares method. The results confirmed that the QSARs for 2-morpholinocarbonyl derivatives and 2- (4-methylpiperazinylcarbonyl) derivatives can be expressed in one model where the steric nature of the 4-and 6-substituents mainly affects both the analgesic and antiinflammatory potencies.
ISSN:0009-2363
1347-5223
DOI:10.1248/cpb.35.402